latest news releases from the newsroom
Actavis Acquires Keri Pharma Generics as Part of its Expansion Strategy in the CEE region
REYKJAVIK, Iceland, Sept. 30, 2005 (PRIMEZONE) -- Actavis Group (ICEX:ACT), the international generic pharmaceutical company, today announces that it has acquired the generic business of the Hungarian pharmaceutical company, Keri Pharma. Financial details were not disclosed.Keri Pharma was founded in 1991 and specialises in the development, sales and marketing of generic pharmaceuticals in the central eastern European region. The majority of the Company's sales are in Hungary, but it also exports to Poland, Slovenia, Slovak Republic, Czech Republic and the Baltic states. The company employs around 80 people and has over 20 products on the market, with a further 23 in the pipeline. The portfolio consists mainly of Central nervous system (CNS), Cardiovascular and Rheumatology products. Keri has a strong business development unit while production is outsourced to third parties. Keri will launch the first two Actavis products this year, as a customer of Medis, Actavis' Third-party sales division. The Company's products are fully compliant with EU requirements, and now there is a possibility to launch some of these products into other Actavis markets.
Vodafone Sverige AB
Ingram Micro to Distribute Vodafone Sweden's Datacoms Products
STOCKHOLM, Sweden, Sept. 30, 2005 (PRIMEZONE) -- Vodafone Sweden and Ingram Micro in Sweden have entered a collaboration which makes Ingram Micro distributor of Vodafone Sweden's mobile products for businesses (including Vodafone Swedens's 3G data card and Blackberry(R) products) to their IT retailers. For the end-customer this means that IT-products and mobile solutions will all be available in one place.
Nomination Committee for 2006 Annual Shareholders' Meeting of Skanska AB
STOCKHOLM, Sweden, Sept. 30, 2005 (PRIMEZONE) -- In accordance with a decision in the Skanska's Annual Shareholders' Meeting 2005, the Chairman of the Board has asked five of the largest shareholders to appoint one representative each that, together with the Chairman will form a Nomination Committee. The task of the Nomination Committee is to propose a Board of Directors and also remuneration to the Board of Directors. The proposals are to be decided upon in the Annual Shareholders' Meeting 2006.
Active Biotech: Confirmed ANYARA Tumor PET Localization in Cancer Patients
STOCKHOLM, Sweden, Sept. 30, 2005 (PRIMEZONE) -- In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed.Using Positron Emission Tomography (PET) and radioactively labeled ANYARA, drug concentrations in tumor and normal tissues of individual patients have been measured for the first time, demonstrating that ANYARA localizes to tumors that express the target antigen 5T4. The study is ongoing at Paterson Institute for Cancer Research and at Christie Hospital, Manchester, UK and the first results from this study will be presented at the NCRI (National Cancer Research Institute) conference held in Birmingham, UK on October 2-5.
Port of Houston Authority
PHA Commission Delivers Bayport, Security, Capital Improvement Matters
HOUSTON, Sept. 29, 2005 (PRIMEZONE) -- The Port of Houston Authority (PHA) commission approved several recommendations involving contract awards, bids and proposals, professional services and general administrative and operational matters during its public meeting on Thursday, September 29, 2005. Chairman Jim Edmonds presided over the meeting with Vice Chairman Kase Lawal, Commissioner Steve Phelps, Commissioner Jim Fonteno, Commissioner Jimmy Burke, Commissioner Cheryl Thompson-Draper, and Commissioner Janiece Longoria.